Quantcast

Latest Haemophilia A Stories

2014-07-07 16:23:47

First Recombinant Treatment Approved in US for Patients With GT With Refractoriness to Platelet Transfusions, With or Without Antibodies to Platelets PLAINSBORO, N.J., July 7, 2014 /PRNewswire/ -- Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved NovoSeven(®) RT (Coagulation Factor VIIa [Recombinant]) as the first recombinant treatment for bleeding episodes and perioperative management in patients with Glanzmann's Thrombasthenia (GT) with refractoriness to...

2014-05-05 20:26:32

LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024http://www.reportbuyer.com/pharma_healthcare/diseases/bleeding_disorders_world_pharmaceutical_industry_market_2014_2024.htmlReport DetailsTreating abnormal bleeding - this new report shows you trends, R&D outlooks, and sales forecastsTreatments for bleeding - what're their prospects? Visiongain's new report gives you...

2013-10-15 23:34:20

Dr. Gary McClain is speaking at a family camp for children with hemophilia and active inhibitors and their families on October 17-20 at Victory Junction in Randleman, NC. (PRWEB) October 15, 2013 Dr. Gary McClain is speaking at a family camp for children with hemophilia and active inhibitors and their families on October 17-20 at Victory Junction in Randleman, NC. A specialist in the emotional and spiritual impact of chronic and catastrophic illnesses, Gary McClain, PhD, developed...

2011-05-19 15:00:00

KING OF PRUSSIA, Pa., May 19, 2011 /PRNewswire/ -- Advances that CSL Behring is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with hemophilia A and B will be the topic of an oral presentation at an international medical congress on May 22, 2011. CSL Behring is a global biotherapeutics company specializing in plasma-derived and recombinant therapies and is a subsidiary of CSL Limited (ASX:CSL). CSL627, a unique single-chain recombinant...

2011-05-17 18:00:00

KING OF PRUSSIA, Pa., May 17, 2011 /PRNewswire/ -- CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies and a subsidiary of CSL Limited (ASX: CSL), is a recipient of the National Organization for Rare Disorders (NORD) 2011 Corporate Award. The award was presented this evening at the NORD Partners in Progress Celebration 2011 for "new treatments brought to market for patients with rare diseases." (Logo:...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related